Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Arcutis Biotherapeutics (ACRT) reported Q2 2026 net income of $15 million, marking profitability as flagship dermatology drug Zoryve posted $129.9 million in revenue, up 59% year-over-year. The company raised full-year 2026 revenue guidance to $525 million–$540 million following FDA approval to expand Zoryve's label to treat plaque psoriasis in children as young as age 2.

CEO Todd Watanabe sold 4,375 shares for $114,275 on August 3, 2026, in a non-discretionary transaction to cover tax withholding on vesting restricted stock units. The sale was tied to equity compensation mechanics, not a discretionary liquidation.

The pediatric indication broadens Zoryve's addressable market in a space where treatment options for younger patients remain limited. The 59% revenue growth rate and positive net income suggest commercial momentum is accelerating ahead of the label expansion's full impact.